Isis Pharmaceuticals news from FierceBiotech
NewsCholesterol drug delay signals new FDA standards
In what may signal a major shift in FDA standards, Isis and Genzyme say that they expect to add another year to the development timeline for a closely watched cholesterol therapy in order to produce Read more...
ALSO NOTED: MAP touts IIa data; Isis pockets $2M milestone;and much more...
> A surge of hopeful research reports on the potential of stem cells has helped fatten profits at Cryo-Save. The company says its stem cell storage work jumped 41 percent last year. Demand is Read more...
OncoGenex, Isis report Phase II success
OncoGenex and collaborator Isis Pharmaceuticals say that in a Phase II trial, OGX-011, in combination with either docetaxel or mitoxantrone, was well-tolerated as a second-line treatment for patients Read more...
DEALS: Genzyme, Isis ink $1.9B pact
Genzyme, Isis ink $1.9B pact DEALSWHOWITHWHATSCOOPGenzymeIsis Pharmaceuticals$1.9B dealThe deal is for Isis' promising cardiovascular drug mipomersen, its flagship product. Read more...
Genzyme wins Isis pact with $1.9B bid
Shares of Isis Pharmaceuticals rocketed up 45 percent after the biotech announced that Genzyme had signed on as a partner to Read more...
ALSO NOTED: FDA panelist rails against lax enforcement; Micromet's CFO resigns;and much more...
> Remember that scathing report from the FDA's own Subcommittee on Read more...
SPOTLIGHT: Regulus gets CEO
Alnylam Pharmaceuticals and Isis Pharmaceuticals have named Kleanthis G. Xanthopoulos as president and chief executive of their joint venture--Read more...
ALSO NOTED: Antigenics releases positive cancer results; NovaBay raises $24M; Bionovo wraps stock offering; and much more...
> Antigenics says that a Phase I/II trial of cancer vaccine Oncophage delivered positive results, with 11 out of 12 patients exceeding median benchmarks on survival from time of recurrence. Read more...
ALSO NOTED: Novartis cuts 1,260 jobs; Nektar hammered on Exubera decision; and much more...
> Slammed by weak sales last quarter, Novartis announced that it will lay off 1,260 in the U.S. and rearrange its management. Read more...
More good news from RNAi company Isis
Isis has been on a good-news roll lately, and today is no exception. The company announced positive results from a Phase II open-label extension trial of of Read more...
| Press ReleasesGenzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen Breakthrough, Potential Blockbuster Product for High Risk Cardiovascular Patients Genzyme and Isis Read more... PRESS RELEASE: Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes CARLSBAD, Calif., Oct. 18 -- Isis Pharmaceuticals, Inc. today announced that it has Read more... PRESS RELEASE: Isis Pharmaceuticals Says Lipid Drug Appears Safe in Early Trial Isis Pharmaceuticals Says Lipid Drug Appears Safe in Early Trial CARLSBAD, Calif., Oct. 5 -- Isis Pharmaceuticals announced the first safety results from its ongoing Phase 2 open-label extension Read more... PRESS RELEASE: Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients - HeFH Patients on Maximally Tolerated Lipid-Lowering Therapies Experienced 46% Further Reductions in LDL-C Read more... PRESS RELEASE: Isis Pharmaceuticals Gets $5 Million Milestone Payment from Johnson & Johnson Unit Isis Pharmaceuticals Gets $5 Million Milestone Payment from Johnson & Johnson Unit CARLSBAD, Calif., Oct. 2 -- Isis Pharmaceuticals announced today it has earned $5 million from Ortho-McNeil, a Read more... |
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends